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Cancer patients undergo detrimental toxicities and ineffective treatments especially in the relapsed 
setting, due to failed treatment attempts. The development of a tool that predicts the clinical 
response of individual patients to therapy is greatly desired. We have developed a novel patient‑
derived 3D tissue engineered bone marrow (3DTEBM) technology that closely recapitulate the 
pathophysiological conditions in the bone marrow and allows ex vivo proliferation of tumor cells 
of hematologic malignancies. In this study, we used the 3DTEBM to predict the clinical response of 
individual multiple myeloma (MM) patients to different therapeutic regimens. We found that while 
no correlation was observed between in vitro efficacy in classic 2D culture systems of drugs used for 
MM with their clinical efficacious concentration, the efficacious concentration in the 3DTEBM were 
directly correlated. Furthermore, the 3DTEBM model retrospectively predicted the clinical response 
to different treatment regimens in 89% of the MM patient cohort. These results demonstrated that 
the 3DTEBM is a feasible platform which can predict MM clinical responses with high accuracy and 
within a clinically actionable time frame. Utilization of this technology to predict drug efficacy and the 
likelihood of treatment failure could significantly improve patient care and treatment in many ways, 
particularly in the relapsed and refractory setting. Future studies are needed to validate the 3DTEBM 
model as a tool for predicting clinical efficacy.
Personalized medicine is the use of the patient’s own tumor genotype and/or phenotype to create the most appro-
priate therapeutic choice for individual patients. While precision cancer medicine studies have mainly focused 
on genomics, most patients with cancer who receive genomic testing have limited benefit from this  strategy1. 
This is due to the fact that drug sensitivity and resistance depend not only on genomics, but also on epigenetic 
factors, and most importantly the interactions with tumor microenvironment (TME)2. 2D classic tissue culture 
models lack significant biological features of the TME such as oxygen gradients (tumor hypoxia) and drug gradi-
ents, which have critical effect on the sensitivity of cancer cells to therapy in different hematologic malignancies 
such multiple myeloma (MM)3,  leukemia4, and  lymphoma5,6. While synthetic 3D models such as polymeric 
matrices exhibit advantages compared to classic 2D cultures, they utilize non-physiological materials that may 
change the biological properties of the tumor  cells7. In addition, the presence of accessory cells found in the 
TME, aside from the tumor cells, was shown to play a critical role in the TME-induced  resistance2,8. Therefore, a 
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patient-derived 3D model of primary tumor cells, including other accessory cells, without exogenous polymers, 
that truly recapitulates the TME is warranted.
We have previously created a patient-derived 3D tissue-engineered bone marrow (3DTEBM) culture model, 
which is predominantly derived from BM aspirates of patients with hematologic malignancies (Fig. 1A). It utilizes 
autologous BM supernatant to create the 3D matrix, in which we incorporate primary cancer cells, along with 
all the other accessory cells in the BM microenvironment, without the addition of exogenous  materials9. The 
BM cellular and non-cellular constituents recapitulate the malignant TME enabling primary cells progression ex 
vivo9. In addition, the hydrogel-like 3D structure derived from the crosslinking of endogenous fibrinogen results 
in a “soft” culture compared to other synthetic polymers, which better recapitulates the BM  tissue2,10. Moreover, 
the 3D structure recreated oxygen gradients, resembling tumor hypoxic BM niche. It was demonstrated that the 
3DTEBM was able to promote biological effects which were not demonstrated in regular 2D  culture2,10–12, and 
allow the survival and proliferation of freshly isolated or frozen primary cancer cells ex vivo, in both  MM10,12 
and  leukemia11.
The 3DTEBM model was shown to mimic the malignant BM condition in several hematologic malignancies 
including  MM9, acute myeloid leukemia, chronic myeloid leukemia, and chronic lymphocytic  leukemia11, allow-
ing primary cell progression ex vivo and better representation of drug resistance/sensitivity7,9,11. Therefore, the 
Figure 1.  Novel patient-derived 3D Tissue-Engineered Bone Marrow (3DTEBM) used to predict clinical 
efficacy in individual cancer patients for personalized medicine. (A) The 3DTEBM includes all the accessory 
and primary cancer cells found in the bone marrow (BM), as well as growth factors, enzymes, and cytokines 
naturally found in the TME which better recapitulates the BM niche found in patients. (B) Clinical workflow for 
a retrospective study testing 3DTEBM predictability for multiple myeloma (MM) patient clinical response.
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3DTEBM arises as a unique model for ex vivo drug screening and predictive tool to determine clinical efficacy 
in individual cancer patients for personalized medicine.
MM is the cancer of plasma cells within the BM and represents the second most common hematologic 
 malignancy13. Although therapeutic options have significantly broadened over the years, the disease is chal-
lenged by frequent relapses. Relapsed/refractory MM (RRMM) often becomes non-responsive to previous lines 
of treatment and has significantly poorer survival  outcome14. Physicians are faced with a difficult task to choose 
a right treatment regimen for RRMM  patients15. In this study, we aimed to conduct a retrospective study that 
tests the ability of the ex vivo 3DTEBM platform to predict the clinical response in individual MM patients, to 
help decision-making process for RRMM. 3DTEBM cultures were developed for each patient from BM biopsies 
obtained before the start of clinical treatment. Cultures were treated ex vivo with the same treatment regimen 
each patient received clinically. Finally, ex vivo responses in the 3DTEBM were correlated to clinical responses, to 
test overall predictability (Fig. 1B). We hypothesized that the 3DTEBM will be able to predict clinical responses 
of RRMM patients.
Results
Despite the ability of therapeutic agents to eradicate MM in vitro in classic 2D culture models, there is often 
little correlation with clinical activity in patients. To demonstrate this discrepancy between drug efficacy in 
laboratory settings and clinical outcomes, we compared the in vitro efficacious concentration to the clinical 
efficacious concentrations of 10 drugs used for the treatment of MM (Table 1). We defined the efficacious clini-
cal concentration as the steady state plasma drug concentration (Css) reached after administration of clinically 
effective doses. We performed a literature search and determined Css values based on pharmacokinetic data 
from Phase 1 and/or Phase 2 clinical trials (Table 1). Next, we defined the efficacious in vitro concentration as 
the half-inhibitory concentration  (IC50) at 48 h for each drug in MM cell lines. The  IC50 values for the 2D classic 
tissue culture system was determined by both literature search and experimental study. With these information, 
we calculated the correlation between the 2D IC50 values and clinical Css values. We found that there was no 
correlation between the in vitro 2D  IC50 and the clinical Css values, represented by a correlation coefficient of 
 R2 = 0.601 for literature studies (Fig. 2A) and  R2 = 0.019 for experimental study (Fig. 2B).
We then determine the  IC50 values of the same drugs in the 3DTEBM culture system, and their correlation 
with clinical Css values. MM cells lines were cultured within the 3DTEBM in combination with MM patient 
BM microenvironment, and the MM cell survival was determined at 48 h (Fig. 2C). In contrast to 2D tissue 
cultures, we found that the  IC50 values in the 3DTEBM directly correlated with the clinical Css, represented 
by a correlation coefficient of  R2 = 0.993 (Fig. 2D). The individual drug’s dose response curves are also shown 
(Fig. 2E and Supp Fig. 1).
Next, we conducted a retrospective clinical trial to determine if the 3DTEBM platform is able to predict each 
patient’s clinical response by recreating the same treatment regimen ex vivo. 19 RRMM patients with known 
clinical responsiveness to the regimen they received were identified. The patients had a mix of responsiveness: 
patients with partial response (PR), very good partial response (VGPR) and/or complete remission (CR) were 
categorized as “responsive”, while patients with stable disease and/or progressive disease (PD) were categorized 
as “non-responsive”. Patient demographics for the primary MM samples used are shown in Table 2.
We developed 3DTEBM cultures using individual patient’s BM samples collected prior to the start of their 
prescribed treatment regimen. Samples were treated for 4 days with the respective regimen at increasing concen-
trations, and primary cell survival was determined as % of untreated (Fig. 3A). The ex vivo response was given 
back to the clinical teams as “responsive” or ”non-responsive”. To demonstrate the range of ex vivo response we 
observe in the 3DTEBM, primary cell survival curves resulting from 3DTEBM cultures derived from two MM 
patients are presented (Fig. 3B), each of which were treated with the same drug regimen. MM Patient 4 did not 
respond (p-value of 0.9642) to the combination treatment of bortezomib and dexamethasone, while MM Patient 
4 responded to the treatment (p-value of 0.0001). Additionally, survival curves for all 19 patients representing 
their ex vivo response are shown in Supplemental Fig. 2. The clinical teams correlated the ex vivo response for 
each patient with the clinical response.




2D Literature  IC50 
(nM)
Carfilzomib 5 16–18 5.3 19–21
Bortezomib 10 22 5 19,23–25
Ixazomib 15 26,27 15.8 24,28
Panobinostat 10 29,30 31.2 31,32
Lenalidomide 1000 33,34 600 35–37
Pomalidomide 130 38 14,773.7 39,40
Dexamethasone 500 41 11,900.7 42–45
Etoposide 30,000 46,47 28,000.1 48–50
Doxorubicin 3000 51 14,536.8 52–54
Melphalan 2000 55,56 10,000 57–59
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Finally, we developed a summary, highlighting the predictability of patient response by the 3DTEBM ex vivo, 
based on the drug regimen that the patient received clinically. The 3DTEBM model was able to predict the 
response in 89% of the MM patient cohort (Fig. 3C). Particularly, it was able to predict 100% of the non-respon-
sive cases in MM, and 75% in MM responsive cases. A more detailed description of the clinical responses, and 
responses predicted by 3DTEBM for each patient sample are listed in Table 3.
Discussion
The majority of clinical trial failures are due to a lack of drug efficacy (52%)60. The traditional 2D culture sys-
tem does not recapitulate the TME nor the clinical outcomes. In this study, we demonstrated that there was no 
correlation between the in vitro  IC50 values in classic 2D culture systems and the clinically efficacious concen-
trations. These findings could partially explain the discrepancies between drug efficacy in laboratory settings 
and the unsatisfactory clinical outcomes in hematologic malignancies. In contrast,  IC50 values obtained in the 
Figure 2.  The 3DTEBM efficaciously correlates between half maximal inhibitory concentration (IC50) 
and clinical steady state plasma concentration (Css) values of MM drugs. IC50 values determined by (A) 
2D literature research and (B) 2D experimental studies both correlated poorly with clinical Css values. (C) 
Schematic of experimental procedure for determining 3DTEBM IC50 in cell lines. (D) IC50 values determined 
by 3DTEBM correlated well with clinical Css values. (E) 3DTEBM dose response curves for all 10 drugs tested 
in MM1.S cells. Correlation coefficients  (R2) were calculated from linear regression fitting.
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3DTEBM showed direct correlation with clinically efficacious concentrations. This suggests that, unlike regular 
culture systems, the 3DTEBM platform provides a pathophysiologically relevant model that could be used for 
drug development and help predict drug efficacy in individual patients.
Recent studies in the field have suggested a variety of ex vivo approaches to identify drugs with clinical effi-
cacy in hematologic  malignancies61–64. Despite intensive efforts in the field, reliable, cost-effective and simple 
ex vivo model that is applicable in the clinical practice for drug efficacy prediction is still  lacking62. A reliable 
method predicting drug efficacy and the likelihood of treatment failure could significantly improve patient care 
and treatment in many ways particularly in relapsed/refractory setting. Potential benefits will include but not 
limited to avoiding the toxicity and reducing the costs of therapies that prove to be ineffective.
Table 2.  Clinical characteristics of patients with multiple myeloma.
Clinical characteristics All patients (n = 19)





African American 2 (11)
White 17 (89)
Treatment Status Value (%)
Relapse/Progression 19 (100)
Figure 3.  Retrospective predictability for MM patient cohort. (A) Schematic of experimental procedure for 
determining ex vivo response in 3DTEBM utilizing patient unsorted bone marrow mononuclear cells (BMMCs) 
and autologous BM plasma. (B) Example primary MM cell survival for a responsive and a non-responsive MM 
patient sample. Statistical significance is analyzed by single-factor ANOVA; responsive if p < 0.05. (C) Overall 
predictability of patient clinical response for each drug therapy using the 3DTEBM platform.
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In this retrospective study, we demonstrated that the 3DTEBM technology was able to predict clinical thera-
peutic response with 89% accuracy. These results suggest the 3DTEBM as a feasible platform for predicting 
therapeutic responses in MM with a high predictive accuracy within a clinically actionable time frame. Routine 
bone marrow biopsy, in addition to its diagnostic value, can be now utilized in the 3DTEBM as a treatment 
decision-making tool. Such platforms can provide precise clinical insight about the efficacy of different treat-
ment plans in a timely manner (less than a week), and assist physicians to propose the best choice of therapy for 
their individual patients.
3DTEBM is emerging as a promising personalized medicine platform for prediction of clinical responses to 
therapy in individual RRMM patients, not only because of its ability to allow proliferation of patient-derived 
primary tumor cells and its ability to mimic patient’s own pathophysiologic BM TME ex vivo, but also because of 
its accuracy, reproducibility, short turnaround time, high-throughput potential, and low-cost. Future prospective 
studies are needed to validate these significant findings by expanding clinical sample size, and testing the ability 
of the 3DTEBM to prospectively predict effective treatment for improved response in hematologic malignancies.
Methods
Materials and reagents. Lipophilic cell tracer (DiO) was purchased from Invitrogen (Eugene, OR). All 
antibodies used for flow cytometry were purchased from BD Biosciences (San Jose, CA) unless otherwise noted. 
Red Blood Cell (RBC) lysis buffer was purchased from Biolegend (San Diego, CA). All chemicals were pur-
chased from Millipore Sigma (Burlington, MA). All drugs were purchased from Selleck Chemicals (Houston, 
TX), except Daratumumab (Janssen, Beerse, Belgium), which was generously provided to us by the pharmacy 
at Washington University. MM cell lines were obtained from American Type Culture Collection (Manassas, 
Virginia).
Patient primary BM samples. MM pre-treated patient samples were collected under informed consent, 
in concordance with the Institutional Review Boards (IRBs) of Washington University in St. Louis School of 
Medicine (IRB protocol number 201102270). All studies were in accordance with the Declaration of Helsinki. 
Plasma was isolated by centrifugation, and BM mononuclear cells (BMMCs) were isolated by RBC lysis, as 
described  before65. To acquire BM negative fraction cells, BMMCs from MM aspirates were depleted of CD138 
by magnetic beads, as previously  described66.
Cell culture and 3DTEBM culture. MM cell lines, MM.1S, H929, and OPM2, were purchased from 
American Type Culture Collection (Rockville, MD). All cell lines were cultured in RPMI-1640 media (Corning, 
Corning, NY) supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, 100 μg/mL penicillin, and 
100 μg/mL streptomycin. All cells were cultured at 37 °C and in 5% CO2 in a NuAire water jacket incubator 
(Plymouth, MN).
3DTEBM were prepared as previously  described9. Briefly, cells of interest were plated in 96-well plate in a 
mixture of BM supernatant, RPMI media, tranexamic acid, and calcium chloride (10 mg/mL). After the 3D 
matrix cross-links, they were supplemented with media on top and cultured at 37 °C and 5%  CO2. At the end of 
Table 3.  Clinical responses and predictability of 3DTEBM.
Patient Treatment
3DTEBM
Clinical Response PredictiveP-value Response
1 Bort-Dexa 0.9642 Not sensitive PD Yes
2 Bort-Dexa  < 0.0001 Sensitive PR Yes
3 Bort-Dexa 0.4629 Not sensitive PD Yes
4 Bort-Dexa 0.0001 Sensitive PR Yes
5 Bort-Dexa  < 0.0001 Sensitive PR Yes
6 Bort-Dexa 0.3522 Not sensitive PD Yes
7 Carf-Dexa 0.0008 Sensitive VGPR Yes
8 Carf-Dexa 0.7661 Not sensitive PD Yes
9 Carf-Dexa 0.1092 Not sensitive PD Yes
10 Carf-Dexa 0.4130 Not sensitive PD Yes
11 Carf-Doxo 0.0038 Sensitive PR Yes
12 Carf-Doxo 0.1006 Not sensitive PD Yes
13 Carf-Doxo 0.5779 Not sensitive PD Yes
14 Bort-Lena-Dexa 0.5334 Not sensitive PD Yes
15 Lena 0.3361 Not sensitive PR No
16 Lena 0.0236 Sensitive VGPR Yes
17 Carf 0.1405 Not sensitive CR No
18 Poma-Dexa 0.6661 Not sensitive PD Yes
19 Daratumumab 0.5263 Not sensitive PD Yes
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the experiment, matrix were digested by type I collagenase, CountBright absolute counting beads (ThermoFisher) 
were added to each well, and samples were filtered using a 35 um nylon mesh filter and subsequently analyzed 
using flow cytometry (MACSQuant Analyzer 16, Miltenyi Biotec, Bergisch Gladbach, Germany).
Correlation of 2D and 3DTEBM IC50 values with clinical Css values. The drugs used for the correla-
tion study were carfilzomib, bortezomib, ixazomib, panobinostat, lenalidomide, pomalidomide, dexamethasone, 
etoposide, doxorubicin, daratumumab, and melphalan for MM. Summary of 2D-Literature, 2D-Experimental, 
and 3DTEBM  IC50 values, as well as clinical Css values for each drug are shown in Table 1.
The steady state plasma drug concentration (Css) was determined based on pharmacokinetic data from Phase 
1 and/or Phase 2 clinical trials. For 2D-Literature  IC50 values, 48 h  IC50 values of MM cell lines from at least two 
studies were averaged. For 2D-Experimental IC50 values, MM cells (MM.1S, H929, and OPM2) were seeded at 
50,000 cells per well in 96-well plate and treated with or without incremental concentration for respective drugs 
for 48 h. Cell survival was determined by MTT assay as previously  described67. Briefly, MTT solution was added 
to the cells for 3 h, then the stop solution was added to dissolve the formazan crystals overnight. Wells were read 
with SpectraMax i3 multimode microplate spectrophotometer (Molecular Devices, San Jose, CA) at 570 nm.
3DTEBM  IC50 values were found by increasing the concentration of each drug inside and on top of the 
3DTEBM cultures for three different cell lines (MM.1S, H929, and OPM2). 3DTEBM were prepared with DiO-
labeled MM cells (50,000/well), BM negative fraction (50,000/well, pooled from 5 RRMM patients), and BM 
plasma (pooled from 5 RRMM patients), and RPMI media mixed with treatment. After crosslinking of 3DTEBM 
for 2 h, the matrix was supplemented with 10% plasma in RPMI media on top. Drug treatment was performed 
at 0.3X, 1X, 3X, and 10X the Css concentration in the 3DTEBM for 48 h. At the end of the experiment, 3D 
matrix were digested by collagenase and counting beads were added to each well. Each sample was filtered and 
analyzed using flow cytometry for the number or the DiO-labeled cancer cells, and normalized to the number 
of beads. Dose escalation curves were graphed, and the  IC50 concentrations for each drug in the three cell lines 
were determined and averaged to find the final 3DTEBM  IC50 values.
Retrospective MM patient 3DTEBM responses. Patient BM samples (unsorted BMMCs and BM 
plasma) were collected before the start of the clinical treatment regimen. Samples were provided to Cellatrix, 
along with the treatment regimen that each patient received after the BM biopsy; however, Cellatrix was blinded 
to the clinical outcomes. Cellatrix treated each patient sample with the corresponding regimen in the 3DTEBM 
and provided the ex vivo response back to the clinical team (as demonstrated in Fig. 1B).
Patient 3DTEBM were developed by seeding 1 ×  105 BMNCs per well with patient’s autologous BM plasma 
and treated with or without the corresponding drug regimen in increasing concentrations (3X and 10X of Css of 
individual drugs). Following four days of treatment, cultures were digested to retrieve the cells for flow cytometry 
analysis. Samples were stained with CD3, CD14, CD16, CD19 and CD123 (all of which were FITC) in addition 
to CD38 (APC), according to our previously published MM detection  method68. For flow analysis, live cells were 
first gated as FSC-hi. Then, MM cell survival was determined by number of FITC-/APC+ cells, normalized to 
counting beads, and the effect of the drug treatment was calculated as percent of untreated control.
Ex vivo response was analyzed by ANOVA and the responsiveness was provided to the clinical team. The 
clinical response was determined by the clinical team after a cycle of respective regimen, defined according to 
the Criteria of the International Myeloma Working  Group69. The clinical team correlated the ex vivo response 
with the clinical response for each patient.
Statistical analyses. All patient sample data experiments were expressed as means ± standard deviation. 
Sample size was estimated using published guidelines. 3DTEBM experiments were performed in quadruplicates. 
Residuals were used to analyze data normality, and we examined the expected variance by analyzing the variance 
similarity across groups. Statistical significance for comparing ex vivo response of primary cells across different 
concentrations was analyzed using a one-way analysis of variance (ANOVA). P-values < 0.05 were considered 
statistically significant. Correlation between  IC50 and Css values determined by linear regression fitting.
Data availability
All data generated are available upon request.
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